Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR566658 in CA6-Positive Metastatic Triple Negative Breast Cancer
NCT02984683Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Mar 2017
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of SAR566658 in triple-negative breast cancer (TNBC) (2 arms), sponsored by Sanofi. Primary endpoints: Objective Response Rate and Number of Participants With Investigational Medicinal Product (IMP)-Related Predefined Safety Criteria Findings. Started Mar 2017; status: terminated.
02
Drugs
SAR566658
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02984683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02984683.